R
Rednvia
The startup is developing a pharmaceutical approach that repurposes approved anti-diabetes medications to treat calcific aortic valve disease, a condition with no current effective treatment. By leveraging the established safety profiles of these drugs, the company aims to slow or halt disease progression in patients with cardiovascular conditions.
Traction –/10
Seoul, South Korea · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup is developing a pharmaceutical approach that repurposes approved anti-diabetes medications to treat calcific aortic valve disease, a condition with no current effective treatment. By leveraging the established safety profiles of these drugs, the company aims to slow or halt disease progression in patients with cardiovascular conditions.